Robert I. Dowell - Concepedia

Author

Robert I. Dowell

Also Known As

R Dowell, R I Dowell, R I. Dowell, R. DOWELL, R. Dowell, R. I. DOWELL, R. I. Dowell, R.I. Dowell, Robert Dowell, Robert I Dowell

Publications

435

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)Institute of Cancer Research East Cheshire NHS Trust

About

Robert I. Dowell is an author at AstraZeneca (United Kingdom) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	342
2	Natural Sciences	5	5	242
3	Biochemistry	4	4	227
4	Biomolecular Engineering	1	1	15
5	Cell Biology	1	1	21

Robert I. Dowell

Publications

384

Citations

H-Index

Page 1

	Year	Citations
Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody-Directed Enzyme Prodrug Therapy Caroline J. Springer, Robert I. Dowell, P. J. Burke, Journal of Medicinal Chemistry Combinatorial ChemistryPharmaceutical ScienceBioorganic ChemistryOrganic ChemistryPharmacotherapy	1995	90
Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors G. C. CRAWLEY, Robert I. Dowell, Philip N. Edwards, Journal of Medicinal Chemistry Pharmaceutical SciencePharmacotherapyNew SeriesPharmaceutical ChemistryDrug Resistance	1992	84
ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts. D C Blakey, P. J. Burke, D. Huw Davies, PubMed Colorectal Tumor XenograftsImmunologyPathologyImproved SystemTumor Regressions	1996	60
New Mustard Prodrugs for Antibody-Directed Enzyme Prodrug Therapy: Alternatives to the Amide Link Robert I. Dowell, Caroline J. Springer, D. Huw Davies, Journal of Medicinal Chemistry	1996	42
Novel inhibitors of prolyl 4-hydroxylase Robert I. Dowell, Elizabeth M. Hadley Journal of Medicinal Chemistry Aldo-keto Reductase5-Acyl SulfonamidesChemical BiologyEnzymatic ModificationPharmaceutical Chemistry	1992	39
DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767 Noel R. Monks, David C. Blakey, S. East, European Journal of Cancer Tumor BiologyDna Interstrand Cross-linkingTp53 StatusTumour Cell SensitivityMedicine	2002	21
Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease D C Blakey, Philip J. Burke, D. Huw Davies, Biochemical Society Transactions ImmunologyPathologyImmunotherapeuticsImmunotherapyTumor Biology	1995	19
ChemInform Abstract: Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody‐Directed Enzyme Prodrug Therapy (ADEPT). C.J. Springer, Robert I. Dowell, P. J. Burke, ChemInform Medicinal ChemistryPharmaceutical SciencePharmaceutical ResearchWeekly Abstracting ServiceMedicine	1996	15
4-Methoxy-2-methyltetrahydropyrans: chiral leukotriene biosynthesis inhibitors, related to ICI D2138, which display enantioselectivity G. C. CRAWLEY, Malcolm T. Briggs, Robert I. Dowell, Journal of Medicinal Chemistry Pharmaceutical ScienceQuantitative PharmacologyAltmetric Attention ScoreChemical BiologyPharmaceutical Chemistry	1993	14

Page 1